• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Power3 Medical Products in Talks With Industry Leaders to License and Market Its Proprietary Technology for Diagnostic, Disease Detection Blood Tests for Breast Cancer, Alzheimer's and Parkinson's Disease

Posted on: Tuesday, 7 October 2008, 12:00 CDT

Power3 Medical Products, Inc. (OTCBB:PWRM), (www.power3medical.com), today announced that the Company has been contacted by and is currently in talks with leading marketers of early disease detection tests and is confident that the ongoing talks and negotiations will insure the future of the company's primary focus, the commercialization of its proprietary intellectual property, and to enhance shareholder value through product sales and new revenue streams.

"The fruits of our labors are beginning to pay off, in what I would consider to be an unprecedented interest in our diagnostic blood test technologies, especially our early diagnostic test for breast cancer," stated Dr. Ira Goldknopf, President and Chief Scientific Officer of Power3. The company attributes the recent increase of interest in its products to a lecture given by Dr. Goldknopf on Oct. 1, 2008 at a CHI Biomarker Discovery Summit, which addressed technologies for the early detection of breast cancer, as well as Alzheimer's and Parkinson's diseases, utilizing Power3's proprietary protein biomarker technology.

"In addition, October is Breast Cancer Awareness Month and there is a heightened awareness of the need for products such as ours that can detect the disease early and thereby help give the patient opportunities for earlier treatment and reassurance," stated Helen R. Park, Interim CEO of Power3.

About Power3 Medical Products, Inc.

Power3 Medical Products, Inc. (OTCBB:PWRM) (www.Power3Medical.com), is a leading Bio Medical company engaged in the commercialization of cancer and neurodegenerative disease biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. Power3's patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Power3 operates a state-of-the-art CLIA certified laboratory in The Woodlands (Houston), Texas. The Company continues to evolve and enhance its IP portfolio.

Forward-Looking Statement

This press release contains forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in this press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement.

Source: Business Wire

More News in this Category